Shares of AstraZeneca Pharma India surged 7.07% to ₹8,535.50 in early trade on Monday, June 2, after the company posted robust financial results for Q4 FY25 and announced a major revenue milestone.
The company reported a 25.3% year-on-year growth in revenue from operations for the March quarter, reaching ₹480.48 crore. Profit before tax (PBT) rose to ₹84.15 crore, up from ₹54.36 crore in the same quarter last year.
Full-year performance was equally impressive, with AstraZeneca recording a 32% jump in annual revenue. The company also crossed ₹1,700 crore in annual sales for the first time, driven by its innovation-led portfolio and strong growth across therapeutic areas.
In Q4, the oncology segment remained a key growth driver, delivering revenue of ₹315.85 crore, a 31.62% increase YoY. The biopharmaceuticals segment—which includes cardiovascular, renal, respiratory, immunology, and vaccines—saw modest growth of 1.9% to ₹122.74 crore. Meanwhile, the rare disease segment surged to ₹2 crore from ₹0.17 crore YoY, underscoring the company’s diversification strategy.
Sanjeev Panchal, Country President and Managing Director, remarked, “We are pleased to share that our company has, for the first time, crossed the ₹1,700 crore mark ($200 million). Science is sustaining and growing the success of our company, helping us transform the future of healthcare.”
AstraZeneca’s stock has gained over 7% intraday, with a current market cap of ₹210.23 billion and a P/E ratio of 216.82, according to NSE data. The performance reinforces investor confidence in the company’s sustained innovation and strategic growth across key therapeutic segments.